Truist Financial Corp purchased a new position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,530 shares of the biotechnology company’s stock, valued at approximately $221,000.
Several other hedge funds also recently added to or reduced their stakes in BPMC. Empirical Asset Management LLC purchased a new stake in Blueprint Medicines during the 4th quarter valued at about $2,348,000. Stephens Inc. AR acquired a new position in shares of Blueprint Medicines during the fourth quarter valued at approximately $321,000. Massachusetts Financial Services Co. MA raised its holdings in shares of Blueprint Medicines by 48.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company’s stock valued at $23,332,000 after acquiring an additional 82,693 shares during the last quarter. Entropy Technologies LP acquired a new stake in shares of Blueprint Medicines in the third quarter valued at approximately $999,000. Finally, KBC Group NV increased its holdings in shares of Blueprint Medicines by 63.9% in the fourth quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 1,023 shares during the last quarter.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on the company. JPMorgan Chase & Co. raised their price target on Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. StockNews.com cut Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Monday. Needham & Company LLC reaffirmed a “buy” rating and issued a $133.00 price objective on shares of Blueprint Medicines in a report on Thursday, February 13th. HC Wainwright reissued a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, February 14th. Finally, Piper Sandler increased their target price on Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $123.83.
Get Our Latest Stock Analysis on Blueprint Medicines
Insider Buying and Selling
In related news, CEO Kate Haviland sold 1,446 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the sale, the chief executive officer now owns 149,378 shares of the company’s stock, valued at $16,467,430.72. The trade was a 0.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ariel Hurley sold 3,203 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total value of $296,661.86. Following the sale, the insider now directly owns 18,270 shares in the company, valued at approximately $1,692,167.40. The trade was a 14.92 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 48,427 shares of company stock worth $4,837,801. Corporate insiders own 4.21% of the company’s stock.
Blueprint Medicines Trading Down 1.5 %
NASDAQ:BPMC opened at $88.54 on Friday. The business’s 50-day moving average is $99.49 and its two-hundred day moving average is $94.31. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. Blueprint Medicines Co. has a 12 month low of $80.68 and a 12 month high of $121.90. The firm has a market capitalization of $5.66 billion, a PE ratio of -81.98 and a beta of 0.62.
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Research analysts predict that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
See Also
Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Co. (NASDAQ:BPMC – Free Report).
Receive News & Ratings for Blueprint Medicines Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Blueprint Medicines and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
